Financial reports
Current reports
8-K
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program
3 Sep 24
8-K
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
14 Aug 24
8-K
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
14 May 24
8-K
Nasdaq listed (MGX) Business Update Call May 1st, 2024, 5pm ET Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines
1 May 24
8-K
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
27 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Feb 24
Registration and prospectus
424B4
Prospectus supplement with pricing info
12 Feb 24
S-8
Registration of securities for employees
9 Feb 24
S-1/A
IPO registration (amended)
7 Feb 24
8-A12B
Registration of securities on exchange
5 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
S-1/A
IPO registration (amended)
8 Jan 24
S-1
IPO registration
5 Jan 24
DRS/A
Draft registration statement (amended)
11 Dec 23
D
$100.00 mm in equity / Series B-1 Preferred units, sold $95.79 mm, 25 investors
10 Jan 23
D
$175.37M in equity, sold $175.37M, 29 investors
7 Feb 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
9 Feb 24
CERT
Certification of approval for exchange listing
8 Feb 24
SEC STAFF
SEC staff action: Order
8 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
UPLOAD
Letter from SEC
6 Feb 24
CORRESP
Correspondence with SEC
5 Feb 24
CORRESP
Correspondence with SEC
18 Jan 24
CORRESP
Correspondence with SEC
16 Jan 24